Lunacalcipol

Overview

Lunacalcipol (CTA-018), as a vitamin D analogue, has a dual role in the pathogenesis of Chronic Kidney Disease (CKD), as an agonist of vitamin D receptor and an antagonist of cytochrome P450 enzyme 24-hydroxylase . Lunacalcipol binds to VDR and regulates transcriptional activity of VDR by influencing ligand binding affinity, ligand-dependent coactivator recruitment or inhibitory factor dissociation, efficiency of ligand entry into target cells, tissue specificity and different metabolism of ligand. Lunacalcipol can be used in the study of CKD, especially Secondary Hyperparathyroidism (sHPT).

Application

Products | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Signaling Pathways > Vitamin D Related/Nuclear Receptor | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Endocrinology | Products > Research Areas > Others | Products > Signaling Pathways > VD/VDR | Products > Signaling Pathways > Cytochrome P450

Product Information

• Catalog No.: HY-14863
• CAS No.: 250384-82-8
• Molecular Formula: C28H42O4S
• Molecular Weight: 474.70
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source